Lipoic Acid - The latest research - Feb 2026

Evidence Review • Multiple Sclerosis

Alpha-Lipoic Acid (ALA) and Multiple Sclerosis: What the Research Shows

Prepared as an evidence-focused, journal-style overview for patient education and clinician discussion.
Last updated: 18 Feb 2026

Abstract

Background: Alpha-lipoic acid (ALA) is an endogenous mitochondrial co-factor with antioxidant and immunomodulatory actions. Progressive MS is associated with oxidative injury, mitochondrial dysfunction, and chronic innate immune activation, providing a rationale for studying ALA as an adjunct.

Findings: The strongest human signal is a 2-year randomized controlled trial in secondary progressive MS (SPMS) reporting a significantly lower rate of whole-brain atrophy with oral ALA (1,200 mg/day) vs placebo.1 A later phase 2 trial in progressive MS did not demonstrate improvement in walking speed (primary outcome).2 Short-duration biomarker/pharmacokinetic studies suggest effects on immune trafficking markers (e.g., MMP-9) and substantial variability in absorption/exposure between individuals.34

Conclusion: ALA is promising as a neuroprotective adjunct, particularly in SPMS but more research is needed. Symptom relief (fatigue, pain, spasticity) is not consistently demonstrated in robust MS trials; expectations should be realistic and use should be discussed with a clinician—especially with diabetes/glucose-lowering therapy.


1. Why ALA is of interest in MS

MS tissue injury includes both inflammatory demyelination and neurodegeneration. In progressive MS, evidence supports an important role for oxidative stress and mitochondrial dysfunction in sustaining axonal vulnerability and brain volume loss.1314 ALA’s roles in mitochondrial metabolism and redox regulation, plus preclinical anti-inflammatory effects, make it a candidate adjunct aimed at neuroprotection.

Plain-language takeaway: ALA is studied less as a “relapse-stopper” and more as a potential “brain tissue protector,” especially for progressive MS.

2. Proposed mechanisms (what is supported vs what is still uncertain)

Mechanistic work in MS has focused on pathways relevant to immune trafficking into the central nervous system and oxidative injury. In a short randomized MS pilot, ALA exposure correlated with reductions in MMP-9, a molecule associated with leukocyte migration and BBB disruption.3 EAE (animal model) studies show reduced T-cell migration into the spinal cord and disease suppression with ALA.6

  • Most supported (preclinical + early human biomarker): effects on immune trafficking markers (e.g., MMP-9) and inflammatory signaling.36
  • Biologically plausible: antioxidant/mitochondrial support in a disease with demonstrated oxidative and mitochondrial pathology.1314
  • Still uncertain: which MS subtypes and which clinical outcomes (walking, disability scales, cognition) are most likely to benefit in practice.2

3. Clinical evidence in MS

Study Population Design / Duration Dose Main result
Spain et al., 20171 SPMS Randomized, placebo-controlled; 2 years 1,200 mg/day Significantly lower rate of whole-brain atrophy vs placebo; more GI adverse events.
Spain et al., 20262 Progressive MS (PPMS/SPMS) Phase 2 randomized clinical trial; 24 months (Trial dose as per protocol) No improvement in timed walking speed (primary endpoint); continued evaluation of other outcomes/safety.
Yadav et al., 20053 MS (mixed) Randomized pilot; 14 days Oral ALA (varied exposure) Higher ALA serum levels correlated with lower MMP-9; high inter-individual variability.
Yadav et al., 20104 MS pharmacokinetics PK study Up to 1,200 mg Human exposure can reach ranges of interest; variability and formulation effects noted.

How to interpret this: The SPMS atrophy finding is the most compelling signal for ALA in MS.1 However, functional outcomes such as walking speed did not improve in a later progressive MS trial,2 which means ALA should not be framed as a guaranteed symptomatic therapy.

Clinical reality check: An MRI biomarker benefit (like slower atrophy) may matter long-term, but it can be subtle and may not produce immediate “feel it today” improvements.

4. Symptoms: fatigue, pain, spasticity, cognition

Many people explore ALA hoping for improvements in fatigue, neuropathic pain, spasticity, balance, or cognition. Current MS RCT evidence does not consistently demonstrate reliable symptomatic improvement. Major MS guidance describes ALA as promising but not proven and encourages clinician discussion and careful use alongside standard MS care.20

5. Dosing used in MS studies

The best-known SPMS trial used 1,200 mg/day orally (often taken as 600 mg twice daily in practice to improve tolerability, though trial regimens vary).1 Pharmacokinetic work in MS highlights substantial variability in exposure between individuals and potential formulation differences.4

Note: This page is educational and does not provide individualized medical advice. Dosing decisions should be clinician-guided.

6. Safety, tolerability, and interactions

In MS trials, ALA was generally tolerated, but GI side effects were more frequent at higher doses (e.g., nausea, reflux, diarrhea).1 Outside MS, ALA has been used clinically in diabetic neuropathy studies, providing additional safety context at therapeutic doses.22

  • Glucose lowering: ALA can lower blood glucose—use caution with diabetes and glucose-lowering medications.10
  • Absorption variability: food and formulation can affect bioavailability; individuals may experience different exposure at the same dose.104
  • Supplement quality: choose reputable, third-party tested products where possible.

7. Conclusion

ALA is best viewed as a potential adjunct—most plausibly in SPMS—supported by a randomized trial showing slower whole-brain atrophy over 2 years.1 However, later progressive MS trial data did not show improvement in walking speed,2 and consistent symptomatic benefits have not been established. If used, ALA should complement—not replace—evidence-based MS care.


References

  1. Spain RI, Powers K, Murchison C, et al. Lipoic acid in secondary progressive MS: a randomized controlled pilot trial. Neurology: Neuroimmunology & Neuroinflammation. 2017;4:e374. PMID: 28680916. PubMed
  2. Spain RI, et al. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. Neurology. 2026. PMID: 41397213. PubMed
  3. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Multiple Sclerosis. 2005. PMID: 15794388. PubMed
  4. Yadav V, Marracci G, Lovera J, et al. Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. BMC Complementary and Alternative Medicine. 2010. PMCID: PMC3489916. Full text (PMC)
  5. Salinthone S, et al. Comparing bioavailability/bioactivity of forms of lipoic acid in MS (conference report). BMC Complementary and Alternative Medicine. 2012;12(Suppl 1):P239. DOI: 10.1186/1472-6882-12-S1-P239. Article
  6. Marracci GH, Jones RE, McKeon GP, et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats EAE. Journal of Neuroimmunology. 2002;131(1–2):104–114. PMID: 12458042. PubMed
  7. Salinthone S, et al. Lipoic acid bioactivity via cAMP signaling (immune modulation). PLOS ONE. 2010. DOI: 10.1371/journal.pone.0013058. Article
  8. Morini M, Roccatagliata L, Dell’Eva R, et al. Alpha-lipoic acid in prevention/treatment of chronic EAE. Journal of Neuroimmunology. 2004. ScienceDirect (abstract)
  9. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biology & Medicine. 1995;19(2):227–250. PMID: 7649494. PubMed
  10. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta. 2009;1790(10):1149–1160. PMID: 19664690. PubMed
  11. Teichert J, Kern J, Tritschler HJ, et al. Pharmacokinetics of alpha-lipoic acid in severe kidney damage/end-stage renal disease. Journal of Clinical Pharmacology. 2005;45(3):313–328. PMID: 15703366. PubMed
  12. Superti F, et al. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits (review). 2024. PMCID: PMC11505271. Full text (PMC)
  13. Lassmann H, et al. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochimica et Biophysica Acta. 2016. PMID: 26432481. PubMed
  14. Mahad DH, Ziabreva I, Lassmann H, Turnbull DM. Mitochondrial defects in acute multiple sclerosis lesions. Brain. 2008. PMID: 18515320. PubMed
  15. Sormani MP, et al. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology. 2014. PMID: 24006277. PubMed
  16. Ortiz GG, et al. Immunology and oxidative stress in multiple sclerosis. Oxidative Medicine and Cellular Longevity. 2013. PMCID: PMC3794553. Full text (PMC)
  17. Jiménez-Jiménez FJ, et al. Oxidative Stress Markers in Multiple Sclerosis. International Journal of Molecular Sciences. 2024. Article
  18. Xie H, et al. Role of lipoic acid in multiple sclerosis. CNS Neuroscience & Therapeutics. 2022. DOI: 10.1111/cns.13793. Article
  19. ClinicalTrials.gov. Lipoic Acid for Secondary Progressive Multiple Sclerosis (NCT01188811). Record
  20. National Multiple Sclerosis Society. Vitamin, Mineral, and Supplements (includes lipoic acid). Guidance page
  21. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid. Diabetes Care. 1999;22(8):1296–1301. PubMed search

Medical disclaimer: This content is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not start, stop, or change any supplement or medication without discussing it with your clinician—especially if you have diabetes, take glucose-lowering medications, are pregnant/breastfeeding, or have significant comorbidities.